EBS

Emergent BioSolutions Inc. · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-27

Figures on this page computed 2026-11-08 12:12 UTC

Last close

5.90USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-27

6.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
The filing itself
7.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
21.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-K for 2025, filed 2026-02-27
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-27
- 10-Q for 2025, filed 2026-11-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.32 against 0.47 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

All from 100

lens 2 of 9

Sales

152

2016-12-31 to 2025-12-31100 at the start152

Sales: 100.00 on 2016-12-31 to 151.99 on 2025-12-31, up 52%.

Profit

102

2016-12-31 to 2025-12-31100 at the start102

Profit: 100.00 on 2016-12-31 to 101.54 on 2025-12-31, up 2%.

Shares in issue

115

2016-12-31 to 2025-12-31100 at the start115

Shares in issue: 100.00 on 2016-12-31 to 115.01 on 2025-12-31, up 15%.

Sales is at 152, Profit is at 102, Shares in issue is at 115, against 100 in 2016.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-27

Sales, where the first year is 100152
Source
filed
Statement
income
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
The filing itself
Profit, where the first year is 100102
Source
filed
Statement
income
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
The filing itself
Shares in issue, where the first year is 100115
Source
filed
Statement
income
Fiscal year
2025
Accession
0001367644-26-000015
Reported in
USD
The filing itself